This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

This study has been completed.
Information provided by:
Allergan Identifier:
First received: February 22, 2007
Last updated: July 16, 2013
Last verified: July 2013
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Condition Intervention Phase
Glaucoma Ocular Hypertension Drug: bimatoprost 0.03% eye drops Drug: travoprost 0.004% eye drops Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Intraocular Pressure (IOP) [ Time Frame: Month 3 ]
    Intraocular Pressure

Secondary Outcome Measures:
  • Tolerability - Conjunctival Hyperemia [ Time Frame: Month 3 ]
    Conjunctival Hyperemia: Number of participants with at least 1 grade increase in severity from baseline. A five grade scale from 0 to 3 (0 = none, +0.5 = trace, 1 = mild, 2 = moderate, 3 = severe)

Enrollment: 266
Study Start Date: August 2006
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: bimatoprost 0.03% eye drops
bimatoprost 0.03% 1 drop nightly for 3 months
Other Name: Lumigan®
Active Comparator: 2 Drug: travoprost 0.004% eye drops
travoprost 0.004% 1 drop nightly for 3 months
Other Name: Travatan®


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Glaucoma or ocular hypertension in both eyes
  • Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
  • Best-corrected visual acuity of 20/100 or better in each eye
  • Visual field within 6 months of study entry

Exclusion Criteria:

  • Secondary glaucoma
  • Active intraocular inflammation or macular edema
  • Intraocular surgery or laser surgery within the past 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440011

United States, California
San Diego, California, United States
Sponsors and Collaborators
Study Director: Medical Affairs Allergan
  More Information

Responsible Party: Medical Affairs Director, Allergan, Inc. Identifier: NCT00440011     History of Changes
Other Study ID Numbers: MA-LUM01
Study First Received: February 22, 2007
Results First Received: September 25, 2008
Last Updated: July 16, 2013

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents
Antihypertensive Agents processed this record on July 19, 2017